EMD Serono Inc Fact Sheet www emdserono com Contact Heather Hatfield 781 681 2124 by akn18992


									EMD Serono, Inc. Fact Sheet
www.emdserono.com                      Contact:     Heather Hatfield

a driving Force in biopharmaceuticals
EMD Serono, Inc. is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to
improve people’s lives. Through its focus on specialized therapeutic areas, including neurodegenerative diseases, fertility, and metabolic endocrinology,
as well as oncology and autoimmune/inflammatory diseases as emerging areas of expertise, EMD Serono is committed to discovering and developing
innovative products that address unmet medical needs.
EMD Serono has a strong market position in neurodegenerative diseases, with Rebif® (interferon beta-1a) serving as its flagship product. In
endocrinology, EMD Serono markets Saizen® (somatropin (rDNA origin) for injection) and Serostim® (somatropin (rDNA origin) for injection). EMD
Serono also has a full portfolio of products in the area of reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa
for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection).
EMD Serono and its affiliates have more than 30 trials across a global clinical pipeline, with a focus on growing its product portfolio in cancer and
neurodegenerative diseases. With a significant annual investment in research and development, EMD Serono is committed to discovering and bring-
ing to market new and innovative medicines.
Collaborating with other biotechnology and pharmaceutical companies, as well as academic and research institutes, is a core part of EMD Serono’s
strategy. By combining complementary expertise and resources, EMD Serono fosters a partnership environment that enhances value—with the goal
of efficiently bringing new therapeutic innovations to people living with serious diseases like cancer and multiple sclerosis.
With a clear commitment to patients and a leadership presence in the biopharmaceutical industry in the US, EMD Serono’s footprint continues to
grow. EMD Serono has more than 1000 employees around the country, as well as fully integrated commercial, clinical and research operations in the
company’s home state of Massachusetts.
EMD Serono is an affiliate of Merck KGaA, Darmstadt, Germany.

      Neurodegenerative diseases                                                            endocrinology

                                                              reproduCtive HealtH                                 metaboliC disorders

Prescribers and patients should familiarize themselves with product and risk information before using. All products have side effects and may not be
for everyone (refer to product prescribing information for full disclosure). For more information on EMD products and patient support services,
visit www.emdserono.com.
EMD Serono, Inc. Fact Sheet

about merck KGaa                                                                         about merck serono
EMD Serono, Inc. is an affiliate of Merck KGaA, Darmstadt, Germany.                      Merck Serono is actively committed to bringing therapeutic innovations
Merck KGaA is the world’s oldest pharmaceutical and chemical company,                    to patients living with unmet medical needs.
with roots dating back to 1668. From the start of industrial production
                                                                                         Around the world, over 17,500 employees work to discover, develop,
in 1827 to the first research on liquid crystals more than 100 years ago
                                                                                         manufacture and commercialize Merck Serono’s prescription therapies,
to the entry into targeted cancer therapy, many milestones in the
                                                                                         available in over 150 countries. As an internationally recognized
company’s history provide strong evidence of the pioneering spirit of
                                                                                         biotechnology leader, with innovative and successful products, along
the people at Merck.
                                                                                         with a well-stocked and promising development pipeline, Merck
In 2008, Merck KGaA consolidated sales totaled €7.20 billion, across                     Serono's 2008 product sales generated total revenues of €5 billion; 22%
both Pharmaceuticals and Chemicals.                                                      of these earnings were devoted to the pursuit of innovative new thera-
                                                                                         pies through internal research and development, strategic alliances and
The Pharmaceuticals business comprises innovative prescription
medicines for the treatment of cancer, neurological and growth
disorders, cardiovascular diseases, infertility, and other medical                       Merck Serono is the division for innovative small molecules and
conditions and over-the-counter products.                                                biopharmaceuticals of Merck KGaA.
The Chemicals business sector offers chemicals for high-tech
applications: liquid crystals for displays, effect pigments for industry
and cosmetics, analytical reagents and test kits, as well as products
and services along the entire process chain of the pharmaceutical and
biotechnology industry.

 merck serono sales
 €m                                                                  2008                                   2007                       Change in %
 Total revenues                                                     4,987                                  4,458                              12
 Gross margin                                                       4,191                                  3,765                              11
 R&D                                                                1,074                                    879                              22
 Operating result                                                     594                                    357                              66
 Exceptional items                                                   -354                                   -744                             -52
 Free cash flow (FCF)                                                 554                                 -6,505                               —
 FCF                                                                  559                                    774                             -28
 before acquisitions & disposals
 Core ROS in %                                                         11.9                                      8.0

                                                                                                                        Compound Breakdown*
               24                                                         Phase I
                                                                          Phase II                                                       Small
               20             1                                           Phase III                                                    Molecules/
                                                                          In Registration                                              Vaccines/
                                                                                                                           Biologics    Peptides
                              5                                                                                              55%
               16                                                                                                                         45%

               12             5

                4                                     4
                                                                              1                      1       1
                0                                     1                       1                      1       1
                         Oncology           Neurodegenerative   Autoimmune                    Endocrinology
                                                Diseases      and In ammatory

                    * Based on individual compounds in development from Phase I; not based on development programs.                                        09-09

To top